open access

Vol 10, No 4 (2014)
Review paper
Published online: 2014-08-29
Get Citation

The efficacy and safety of vemurafenib in therapy of patients with unresectable cutaneous melanoma in the light of updated results of BRIM-3 trial

Katarzyna Kozak, Piotr Rutkowski
Onkol. Prak. Klin 2014;10(4):196-198.

open access

Vol 10, No 4 (2014)
REVIEW ARTICLES
Published online: 2014-08-29

Abstract

Vemurafenib, inhibitor of the BRAF serine-threonine kinase, is a molecularly targeted drug approved for the treatment of advanced melanoma harboring activating BRAF mutation. Inhibition of the BRAF kinase by vemurafenib leads to reduced signaling through the mitogen-activated protein kinase pathway that plays important role in tumor progression. The BRIM-3 phase III trial evaluating the effectiveness of vemurafenib in patients with metastatic melanoma with BRAF mutations showed significant improvement in progression free survival and overall survival. This review presents extended follow-up results of BRIM-3 trial.

Abstract

Vemurafenib, inhibitor of the BRAF serine-threonine kinase, is a molecularly targeted drug approved for the treatment of advanced melanoma harboring activating BRAF mutation. Inhibition of the BRAF kinase by vemurafenib leads to reduced signaling through the mitogen-activated protein kinase pathway that plays important role in tumor progression. The BRIM-3 phase III trial evaluating the effectiveness of vemurafenib in patients with metastatic melanoma with BRAF mutations showed significant improvement in progression free survival and overall survival. This review presents extended follow-up results of BRIM-3 trial.

Get Citation

Keywords

melanoma, BRAF, inhibitor, vemurafenib

About this article
Title

The efficacy and safety of vemurafenib in therapy of patients with unresectable cutaneous melanoma in the light of updated results of BRIM-3 trial

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 4 (2014)

Article type

Review paper

Pages

196-198

Published online

2014-08-29

Bibliographic record

Onkol. Prak. Klin 2014;10(4):196-198.

Keywords

melanoma
BRAF
inhibitor
vemurafenib

Authors

Katarzyna Kozak
Piotr Rutkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl